SCHEMBL7189013

SCHEMBL7189013

COC(=O)CC(NS(=O)(=O)c1ccccc1)c1cccc(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
ATM Q13315 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
EEF2K O00418 3/20 0.48
ITGB3 P05106 2/20 0.46
ITGAV P06756 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 1/20 0.45
ADAMTS4 O75173 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
TSHR P16473 1/20 0.43
LMNA P02545 1/20 0.43
F2 P00734 1/20 0.43
F10 P00742 1/20 0.43
PRSS1 P07477 1/20 0.43
KAT6A Q92794 2/20 0.42
GAA P10253 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6774065 0.82 ALDH1A1 (0.55) ALDH1A1ATML3MBTL1EEF2KITGB3
SCHEMBL5700833 0.80 ALDH1A1 (0.52) ALDH1A1ATML3MBTL1EEF2KITGB3
SCHEMBL5700825 0.80 ALDH1A1 (0.52) ALDH1A1ATML3MBTL1EEF2KITGB3
SCHEMBL6772863 0.80 EEF2K (0.66) ALDH1A1ATML3MBTL1EEF2KITGB3
SCHEMBL7194134 0.79 MAPT (0.59) ALDH1A1ATML3MBTL1EEF2KMAPT
SCHEMBL2499538 0.79 KCNA5 (0.46) ALDH1A1MAPTTSHRLMNAGAA
SCHEMBL2500897 0.79 KCNA5 (0.46) ALDH1A1MAPTTSHRLMNAGAA
SCHEMBL2933326 0.78 CYP1A2 (0.55) ALDH1A1ATML3MBTL1EEF2KMAPT
SCHEMBL13780961 0.78 CYP1A2 (0.55) ALDH1A1ATML3MBTL1EEF2KMAPT
SCHEMBL7193396 0.78 ADAMTS4 (0.59) ALDH1A1ATML3MBTL1EEF2KMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589972-B2 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US disclosed
EP-1147079-A2 BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS Bayer Aktiengesellschaft (DE) 2001-10-24 EP disclosed
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists SCHOOP ANDREAS (DE) 2001-10-18 US disclosed
US-6291503-B1 β-phenylalanine derivatives as integrin antagonists BAYER AKTIENGESELLSCHAFT (DE) 2001-09-18 US disclosed
WO-2000041469-A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists ITGB4, ITGA4, ITGB2 ALDH1A1 2010/4885ATM 2391/4885L3MBTL1 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.